Hepatology

Clinical evidence, research, and medical intelligence in Hepatology.

FMT Trial Protocol Targets Decompensated Cirrhosis in LiverGut Study

Spain’s LiverGut trial will test whether faecal microbiota transplantation can reduce decompensation and improve transplant-free survival in cirrhosis.

By Dr. A. Nikhil Krishnan, MBBS · Oct 19, 2026 · 5 min read

Hepatology·J Hepatology

Base editing approach targets HFE C282Y in hereditary haemochromatosis

An in vivo lipid nanoparticle base-editing strategy corrected the HFE C282Y mutation in models of hereditary haemochromatosis with…

Oct 19, 2026

Hepatology·Brain

Chronic Liver Disease Skin Findings Study Lacks Abstract Details

Only the study title is available, so no valid clinical findings, methods, or results can be rewritten from…

Oct 19, 2026

Hepatology·Gut

Cirrhosis study maps rapid skeletal muscle loss and mortality risk

In cirrhosis, rapid skeletal muscle loss tracked with ascites, higher MELD-Na, and sharply higher waitlist mortality at 12…

Oct 19, 2026

Hepatology·Gut

Gut Microbiome and Genetic Crosstalk in MASLD and HCC

A Gut review examines how microbiome shifts, host genetics, and epigenetic changes interact across MASLD, fibrosis, cirrhosis, and…

Oct 19, 2026

Hepatology·Gut

Gut Microbiome Review Refocuses Cirrhosis Diagnosis and Therapy

A review in Gut examines how bacteria, fungi, and viruses shape cirrhosis progression and how microbiome-based strategies may…

Oct 18, 2026

Hepatology·Gut

China population survey examines liver fibrosis and steatosis with hepatitis B or C

A population-based Chinese survey assessed the burden of liver fibrosis and steatosis among people with hepatitis B or…

Oct 18, 2026

Hepatology·Lan Resp

KIF12 linked to organelle positioning in human cholangiocytes and liver disease

A mechanistic study identifies KIF12 as a regulator of mitochondria, lysosome, and cilia localisation in human cholangiocytes, with…

Oct 18, 2026

Hepatology·ScienceDaily

DT-109 Reverses Fatty Liver Disease by Repairing the Gut

DT-109 reversed severe fatty liver disease in animal studies by restoring the gut barrier and limiting ammonia-driven liver…

Oct 18, 2026

Hepatology·ScienceDaily

UBE2N enzyme may slow fatty liver disease progression to MASH

A preclinical study identifies UBE2N as a liver enzyme that may limit fat buildup, inflammation and scarring in…

Oct 18, 2026

Hepatology

Clinical evidence, research, and medical intelligence in Hepatology.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.